The COVID pandemic truly highlighted the absence of a practical solution to accurately determine an individual’s risk of developing breast cancer between screenings, as several medical societies recommended last year that women of ‘average risk’ postpone mammograms. “The need for technology like this has never been greater. Results include the woman’s absolute breast cancer risk score and breast cancer risk category. All of this information is within a woman’s screening mammogram, making risk assessment simple. ProFound AI Risk utilizes breast complexity findings, automated breast density and age in order to calculate a woman’s short-term, absolute risk of breast cancer. 4,5,6 The latest generation of ProFound AI Risk offers the potential to address these racial disparities and improve outcomes for women, including those who may have higher risks of developing cancers between screenings due to genetic predispositions.” “Studies show African American women have an approximately 40% higher risk of dying from breast cancer, and they are disproportionately affected by more aggressive subtypes, such as triple-negative breast cancer and inflammatory breast cancer, compared to white women. “Factoring in a woman’s racial and ethnic background adds another dimension of personalization that allows clinicians to stratify risk in a more inclusive way,” added Stevens. The ability to factor in clinically relevant global screening guidelines and more than 15 country incidence and mortality reference tables, including ethnicities, for alignment with that country’s general population.The ability to calculate short-term (one-, two- or three-year) absolute risk based on either 2D or 3D mammography images.The latest version of ProFound AI Risk offers expanded features, including:
#Icad mammography software#
The latest generation of ProFound AI Risk offers the ability to calculate a short-term risk estimation for 3D mammography, with greater accuracy compared to both the previous version of the risk software based on 2D mammography and traditionally used risk models. We believe these solutions will be increasingly relevant in the years ahead, as mammography begins to transition from what is primarily an age-based screening paradigm today to a more effective and efficient risk-adjusted screening paradigm.” “We believe these technologies will lead to more appropriate utilization of supplemental imaging and biopsies, less anxiety for women, and decreased costs to the system overall.
“ProFound AI Risk and PowerLook Density Assessment have the potential to truly transform personalized breast cancer screening and risk stratification as we know it,” said Stacey Stevens, President of iCAD, inc.
The latest generation of PowerLook Density Assessment is the world’s first and only multi-vendor deep learning automated breast density assessment algorithm using synthetic images generated from 3D mammography. ProFound AI Risk is the world’s first commercially available clinical decision support tool that provides an accurate 1, 2 short-term breast cancer risk estimation that is truly personalized for each woman, based only on a 2D or 3D mammogram. Both technologies offer improved accuracy and enhanced functionality compared to previous versions of the software. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI ® Risk for digital breast tomosynthesis (DBT), or 3D mammography, as well as an updated version of PowerLook ® Density Assessment. Technology provides critical, risk-adaptive solutions for clinicians facing complex screening challenges presented by the COVID-19 pandemic Latest generation of ProFound AI Risk offers greater accuracy and ethnically inclusive precision screening
0 kommentar(er)
